Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandro Arana

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Pharmacotherapy|May 4, 2018
Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort StudyAlejandro Arana, Andrea V Margulis, Lisa J McQuay, et al.
Epidemiology (Cambridge, Mass.)|May 26, 2018
Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United KingdomAndrea V Margulis, Joan Fortuny, James A Kaye, et al.
Epidemiology (Cambridge, Mass.)|November 30, 2018
Proportions of Cancer Cases in Primary Care, Hospital, and Cancer Registry Data Among Patients Treated for Overactive BladderAndrea V Margulis, Joan Fortuny, James A Kaye, et al.
Pharmacoepidemiology and Drug Safety|October 22, 2020
Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United KingdomAlejandro Arana, Andrea V Margulis, Cristina Varas-Lorenzo, et al.
Epidemiology (Cambridge, Mass.)|November 15, 2017
Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United KingdomAndrea V Margulis, Joan Fortuny, James A Kaye, et al.
Therapeutic Advances in Neurological Disorders|January 28, 2025
A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status updateKerstin Hellwig, Melinda Magyari, Thomas M MacDonald, et al.
Pharmacoepidemiology and Drug Safety|July 26, 2018
Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and GermanyJordi Castellsague, Beatriz Poblador-Plou, Maria Giner-Soriano, et al.
Plos One|September 28, 2018
Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United KingdomAndrea V Margulis, Marie Linder, Alejandro Arana, et al.
Drug Safety|December 17, 2022
Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingCatherine B Johannes, Daniel C Beachler, J Bradley Layton, et al.
Drug Safety|December 30, 2022
Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingHeather E Danysh, Catherine B Johannes, Daniel C Beachler, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Pharmacotherapy|May 4, 2018
Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort StudyAlejandro Arana, Andrea V Margulis, Lisa J McQuay, et al.
Epidemiology (Cambridge, Mass.)|May 26, 2018
Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United KingdomAndrea V Margulis, Joan Fortuny, James A Kaye, et al.
Epidemiology (Cambridge, Mass.)|November 30, 2018
Proportions of Cancer Cases in Primary Care, Hospital, and Cancer Registry Data Among Patients Treated for Overactive BladderAndrea V Margulis, Joan Fortuny, James A Kaye, et al.
Pharmacoepidemiology and Drug Safety|October 22, 2020
Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United KingdomAlejandro Arana, Andrea V Margulis, Cristina Varas-Lorenzo, et al.
Epidemiology (Cambridge, Mass.)|November 15, 2017
Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United KingdomAndrea V Margulis, Joan Fortuny, James A Kaye, et al.
Therapeutic Advances in Neurological Disorders|January 28, 2025
A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status updateKerstin Hellwig, Melinda Magyari, Thomas M MacDonald, et al.
Pharmacoepidemiology and Drug Safety|July 26, 2018
Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and GermanyJordi Castellsague, Beatriz Poblador-Plou, Maria Giner-Soriano, et al.
Plos One|September 28, 2018
Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United KingdomAndrea V Margulis, Marie Linder, Alejandro Arana, et al.
Drug Safety|December 17, 2022
Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingCatherine B Johannes, Daniel C Beachler, J Bradley Layton, et al.
Drug Safety|December 30, 2022
Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingHeather E Danysh, Catherine B Johannes, Daniel C Beachler, et al.
Pageof 4